Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ALXO vs FDMT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ALXO Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 3–5 Matrix Metrics)

ALXO Overall Winner 6-Pillar Tally: ALXO 3 – 2 FDMT (1 Tie) Matrix Metrics: ALXO 3 – 5 FDMT

As of Nov 16, 2026, ALX Oncology Holdings Inc. (ALXO) is the stronger overall head-to-head candidate over 4D Molecular Therapeutics, Inc. (FDMT) in the Tradestie Institutional Equity Comparison Engine, winning 3–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). ALXO carries a Unified Composite Score of 63.1/100 (BUY) at $0.95 (N/M Forward P/E, 0.0% operating margin), whereas FDMT carries 51.3/100 (HOLD) at $11.65 (N/M Forward P/E, -222.7% operating margin).

  • Growth vs. Quality Trade-Off: ALXO earns the overall head-to-head edge with a stronger Unified Composite Score (63.1/100 BUY vs. FDMT 51.3/100 HOLD) and 1.46β · 117% Vol risk profile, whereas FDMT leads top-line expansion (+4505.6% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: ALXO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.0); meanwhile FDMT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ALXO vs FDMT
ALXO NASDAQ Head-to-Head Winner
ALX Oncology Holdings Inc. Common Stock
Pharmaceutical Preparations
$0.95
-9.07% 1D
Market Cap $149.3M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.46β · 117% Vol
Unified Composite Score
63.1 / 100 BUY
Tech 50.0 Fund 61.0 Flow 68.0 Mom 70.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -20.0%), weak momentum, RSI 37
RSI-14: 37.0 · SMA20: $1.18 · SMA50: $1.33
FDMT NASDAQ
4D Molecular Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$11.65
-4.74% 1D
Market Cap $669.3M
TTM Revenue $96M
Forward P/E N/M
Beta / 30D Vol 1.89β · 90% Vol
Unified Composite Score
51.3 / 100 HOLD
Tech 51.0 Fund 47.0 Flow 66.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.3%), weak momentum, RSI 45
RSI-14: 44.9 · SMA20: $12.10 · SMA50: $13.07

6-Pillar Scorecard Institutional Category Breakdown (ALXO 3 – 2 FDMT)

Columns: Metric · ALXO · FDMT
1. Valuation Multiples FDMT
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 6.6x
2. Growth & Scale FDMT
Revenue Growth (YoY) -100.0% +4505.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $96M
Market Cap $149.3M $669.3M
3. Profitability & Quality ALXO
Gross Margin N/A N/A
Operating Margin 0.0% -222.7%
Net Profit Margin 0.0% -208.6%
Return on Equity (ROE) -80.7% -56.7%
4. Balance Sheet & Cash Flow ALXO
Cash Generation (TTM) -$71M -$156M
Cash Flow Margin N/A N/A
Net Cash / Leverage $13M Net Cash $31M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ALXO
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 146.2% (20th %ile) 82.4% (10th %ile)
Put/Call OI Skew N/A 5.16x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ALXO (3) vs FDMT (5)
Institutional Metric ALXO FDMT Criterion Row Edge
Market Capitalization
Scale
$149.3M $669.3M Larger Scale FDMT
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-100.0% +4505.6% Higher Growth FDMT
Operating Margin (TTM)
Profitability
0.0% -222.7% Higher Margin ALXO
Net Profit Margin
Profitability
0.0% -208.6% Higher Margin ALXO
Return on Equity (ROE)
Capital Efficiency
-80.7% -56.7% Higher ROE FDMT
52-Week Range Position
Momentum
5% ($1–$3) 47% ($7–$17) Stronger Trend FDMT
Beta / 30D Volatility
Risk Regime
1.46β · 117% Vol 1.89β · 90% Vol Lower Realized Risk FDMT
Unified Institutional Score
Composite Signal
63.1 / 100 (BUY) 51.3 / 100 (HOLD) Higher Composite ALXO
Trailing 12M Revenue (USD)
Operating Scale
N/A $96M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 6.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$71M ($13M Net Cash) -$156M ($31M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon FDMT +6.74 pp
ALXO: -10.78% · FDMT: -4.04%
3M Horizon FDMT +33.67 pp
ALXO: -54.53% · FDMT: -20.86%
6M Horizon FDMT +91.99 pp
ALXO: -52.72% · FDMT: +39.27%
1Y Horizon FDMT +35.81 pp
ALXO: -22.48% · FDMT: +13.33%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ALXO Revenue FDMT Revenue ALXO Op. Margin FDMT Op. Margin Margin Leader
FY2018 $0M N/A -662.0% N/A ALXO
FY2019 $0M $10M -400.0% -729.4% ALXO
FY2020 $0M $10M -3694.0% -424.0% FDMT
FY2021 N/A $20M N/A -395.5% FDMT
FY2022 N/A $0M N/A -3516.5% FDMT
FY2023 N/A $20M N/A -544.6% FDMT
FY2024 N/A $0M N/A -507678.4% FDMT
FY2025 N/A $90M N/A -187.2% FDMT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ALXO BREAKDOWN
93d in phase · OBV NEUTRAL
Current IV 146.2%
IV Percentile 20th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ALXO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
FDMT BREAKDOWN
62d in phase · OBV NEUTRAL
Current IV 82.4%
IV Percentile 10th %ile
Put/Call OI Skew 5.16x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact FDMT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ALXO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $149.3M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
FDMT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $669.3M market capitalization and -222.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ALXO vs FDMT Key Questions & Quantitative Answers

As of Nov 16, 2026, ALX Oncology Holdings Inc. (ALXO) is the stronger overall head-to-head candidate over 4D Molecular Therapeutics, Inc. (FDMT) in the Tradestie Institutional Equity Comparison Engine, winning 3–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). ALXO carries a Unified Composite Score of 63.1/100 (BUY) at $0.95 (N/M Forward P/E, 0.0% operating margin), whereas FDMT carries 51.3/100 (HOLD) at $11.65 (N/M Forward P/E, -222.7% operating margin). Growth vs. Quality Trade-Off: ALXO earns the overall head-to-head edge with a stronger Unified Composite Score (63.1/100 BUY vs. FDMT 51.3/100 HOLD) and 1.46β · 117% Vol risk profile, whereas FDMT leads top-line expansion (+4505.6% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ALXO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.0); meanwhile FDMT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

FDMT leads the Growth & Scale pillar: ALXO posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with FDMT at +4505.6% YoY revenue growth and +0.0% YoY earnings growth on $96M TTM revenue (N/A gross margin, -222.7% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ALXO cumulative revenue shifted N/A while FDMT shifted +800.0%. In operating R&D and SG&A reinvestment, ALXO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for FDMT.

FDMT screens cheaper on headline valuation multiples. ALXO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas FDMT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ALXO (-80.7% ROE) versus FDMT (-56.7% ROE) capital efficiency.

In options market volatility and institutional positioning, ALXO carries 146.2% implied volatility (20th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.46β · 117% Vol realized risk). By comparison, FDMT carries 82.4% implied volatility (10th %ile, Compressed (<25th %ile)), a 5.16x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.89β · 90% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.